Go to the list of all blogs
Serhii Bondarenko's Avatar
published in Blogs
Jun 07, 2023
Swing vs Trend: JNJ (3.04%) and MRK(6.71%) Performance Comparison & Future Predictions

Swing vs Trend: JNJ (3.04%) and MRK(6.71%) Performance Comparison & Future Predictions

Based on the provided information, it appears that the Swing Trader strategy focusing on medium volatility stocks for active trading has generated a return of 3.04%. On the other hand, the Trend Trader strategy concentrating on popular stocks, utilizing both technical analysis (TA) and fundamental analysis (FA), has achieved a return of 6.71%.

Here's a breakdown of the comparison:

  1. Strategy Focus:

    • Swing Trader: The focus is on medium volatility stocks. This indicates that the strategy seeks to take advantage of price fluctuations in stocks that exhibit moderate price swings.
    • Trend Trader: The focus is on popular stocks. This implies that the strategy identifies and trades stocks that are currently in favor or experiencing upward momentum.
  2. Return on Investment:

    • Swing Trader: The return generated by this strategy is 3.04%. This means that for every dollar invested, the strategy has yielded a profit of approximately 3.04 cents.
    • Trend Trader: The return achieved by this strategy is 6.71%. This indicates that for every dollar invested, the strategy has generated a profit of around 6.71 cents.
  3. Approach:

    • Swing Trader: The strategy likely combines both technical analysis (TA) and fundamental analysis (FA). Technical analysis involves analyzing price charts, patterns, and indicators to identify potential trading opportunities. Fundamental analysis involves evaluating a company's financial health, industry trends, and other relevant factors to determine its intrinsic value.
    • Trend Trader: The strategy also utilizes both technical analysis (TA) and fundamental analysis (FA). This means that it likely employs similar methods as the Swing Trader strategy in terms of analyzing price trends and company fundamentals.

Based on the provided returns, the Trend Trader strategy has outperformed the Swing Trader strategy, achieving a higher return on investment. However, it's important to note that this comparison is based solely on the given returns and does not take into account other factors such as risk management, trading costs, market conditions, or the time period over which the returns were generated. Therefore, further analysis would be required to fully evaluate the effectiveness and suitability of these trading strategies.

When delving into the robust pharmaceutical industry, one can't overlook the performances of prominent players Johnson & Johnson (JNJ) and Merck & Co. (MRK). Both these behemoths have made considerable strides in this highly competitive sector, showing distinctive trading styles and presenting opportunities for different types of traders.

Starting with a swing trading perspective, JNJ with a medium volatility rating of 3.04%, posted a weekly price growth of 1.70%. This outperformed the average weekly price growth of 1.11% across the entire Major Pharmaceuticals industry. With its relatively moderate fluctuations, JNJ represents an appealing choice for active traders who thrive on leveraging price swings over a short period. The company's imminent earnings report on July 20, 2023, is anticipated to offer further insights into its financial health and potential future trading volatility.

In contrast, trend traders might find MRK more fitting to their trading style. As a highly popular stock in the market with a 6.71% volatility rating, MRK exhibited a weekly price growth of 1.31%. Despite this figure being slightly below JNJ's growth, it still surpassed the industry's average. This growth, combined with the upward trajectory often favored by trend traders, paints a compelling picture for MRK. Investors and traders alike will be keenly awaiting MRK's earnings report due on August 01, 2023, as it may hint at future price trends.

Reflecting on the broader industry context, it is crucial to note that the average monthly price growth in the Major Pharmaceuticals industry was negative, at -0.41%. However, the industry rebounded with quarterly price growth of 1.37%. This recent uplift indicates a potential shift in momentum that could benefit both JNJ and MRK, suggesting the industry is on a recovery path.

A noteworthy aspect of the comparative analysis of these two giants is their correlation. JNJ and MRK show a loose correlation of 62%, indicating that while they often move in the same direction, their movements are not identical. This level of correlation offers diversification benefits to an investor's portfolio.

Both JNJ and MRK showcase intriguing prospects in their distinctive ways. Swing traders may find the medium volatility and consistent growth of JNJ attractive, while trend traders could be drawn to MRK's popularity and greater volatility. Given the signs of recovery in the Major Pharmaceuticals industry and upcoming earnings reports, both stocks warrant careful observation in the coming weeks.

Related Ticker: JNJ

Contributor

Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.


JNJ in downward trend: price dove below 50-day moving average on September 30, 2026

JNJ moved below its 50-day moving average on September 30, 2026 date and that indicates a change from an upward trend to a downward trend. In 18 of 32 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 56%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on JNJ as a result. In 44 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 53%.

The Moving Average Convergence Divergence Histogram (MACD) for JNJ turned negative on September 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 19 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 41%.

The 10-day moving average for JNJ crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 47%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where JNJ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 40%.

The Aroon Indicator for JNJ entered a downward trend on October 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where JNJ's RSI Oscillator exited the oversold zone, 10 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 33%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +2.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where JNJ advanced for three days, in 164 of 354 cases, the price rose further within the following month. The odds of a continued upward trend are 46%.

JNJ may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 5 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 63, placing this stock better than average.

The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.710) is normal, around the industry mean (19.199). P/E Ratio (31.549) is within average values for comparable stocks, (34.793). Projected Growth (PEG Ratio) (2.852) is also within normal values, averaging (5.738). Dividend Yield (0.019) settles around the average of (0.025) among similar stocks. P/S Ratio (6.658) is also within normal values, averaging (4.033).

The Tickeron SMR rating for this company is 37 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. JNJ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), AstraZeneca PLC (NYSE:AZN), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 200.13B. The market cap for tickers in the group ranges from 4.8K to 1.06T. LLY holds the highest valuation in this group at 1.06T. The lowest valued company is NEWG at 4.8K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was -2%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was 7%. ABBV experienced the highest price growth at 4%, while SCLX experienced the biggest fall at -22%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was -22%. For the same stocks of the Industry, the average monthly volume growth was 24% and the average quarterly volume growth was -28%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 28
P/E Growth Rating: 53
Price Growth Rating: 55
SMR Rating: 59
Profit Risk Rating: 63
Seasonality Score: 1 (-100 ... +100)
View a ticker or compare two or three
JNJ
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

an investment holding company with interests in health care products

Industry PharmaceuticalsMajor

Industry
Pharmaceuticals Major
Address
One Johnson & Johnson Plaza
Phone
+1 732 524-0400
Employees
138200
Web
https://www.jnj.com
Interact to see
Advertisement
The Bitwise Solana Staking ETF (BSOL) advanced roughly 18% over the trailing 30 days, closely tracking a sharp rally in Solana (SOL). The move extends a broader recovery, with BSOL up approximately 77% over the past three months from its mid-2026 trough.
MSTY is an actively managed single-stock option income ETF (exchange-traded fund) that writes call options on Strategy (MSTR), formerly MicroStrategy, to generate current income. The portfolio is anchored by U.S. Treasury bills and MSTR option contracts rather than a diversified basket of equities, concentrating exposure in one volatile underlying.
AMDL has surged roughly +64% over the past 30 days, from about $47.59 to $78.10, mirroring a powerful rally in its sole underlying stock, AMD . The fund is a leveraged single-stock ETF (exchange-traded fund) designed to deliver 2x the daily return of AMD, amplifying both gains and losses.
TSMX, a 2x daily leveraged single-stock ETF (exchange-traded fund), rose roughly +19% over the trailing 30 days, rebounding sharply from mid-September lows. The fund seeks 200% of the daily return of TSM (Taiwan Semiconductor Manufacturing), meaning its moves are roughly double the underlying stock's daily swings.
Contracted revenue anchor: A roughly $3.2 billion, seven-year LNG (liquefied natural gas) supply agreement with Puerto Rico has received final approval, providing multi-year cash-flow visibility if execution stays on track. Project pipeline inflection: Upcoming milestones include the Barcarena and PortoCem power plants in Brazil, a potential Gás Sul terminal restart, and optimization of the company's modular "Fast LNG" (FLNG) liquefaction fleet.
AMD (Advanced Micro Devices) designs central processing units (CPUs), graphics processing units (GPUs), and AI accelerators, while LRCX (Lam Research) supplies the wafer-fabrication equipment used to build advanced chips. AMD has delivered strong double-digit revenue growth on AI data-center demand, but its shares trade with elevated expectations that can trigger sharp reactions around earnings.
Origination momentum: Velocity Financial enters 2026 off record annual originations of roughly $2.7 billion (up about 48%), positioning it to keep gaining share in a fragmented investor-loan market. Credit normalization is the central watch item: Nonperforming loans fell toward the 8.5% range of portfolio unpaid principal balance (UPB), but asset quality remains the primary swing factor for earnings.
Turnaround milestone ahead: Management has pointed to reaching cash generation in 2027, making the pace of cost discipline and margin recovery the central question for the stock forecast. Fresh capital supports execution: A recently announced $45.5 million equity financing, with participation from management and a single institutional investor, strengthens the balance sheet as the company funds its transformation.
NFE closed at $5.51, down -6.13% during Tuesday's regular session, extending a slide that has pushed shares near a 52-week low. Primary catalyst: the company disclosed its Fast LNG unit is offline after a gas-turbine mechanical failure, with return to service not expected until Q4.
The central $11 target is the arithmetic mean of four verified analyst price targets, rounded from roughly $10.75. With the stock near $2.06, reaching $11 would require an upside of more than 400%, an extremely large move.
The $23 central target is the rounded arithmetic mean of four verified analyst price targets, which average $23.25. The latest verified price is around $9.57, meaning the target implies roughly 140% upside—a very large move.
NXH closed down -11.17% (-$0.23) to $1.83 on Oct 6, the most recent regular session, extending a steep two-day decline. Selling continued as investors digested the mutual termination of the Fathom Holdings merger and a dilutive $45.5M registered direct offering of ~16.5M shares at $2.76.
AMD is a large-cap designer of CPUs (central processing units) and GPUs (graphics processing units) competing directly with Nvidia in the AI accelerator market, while FORM is a small-cap provider of semiconductor test and measurement equipment, primarily probe cards. AMD's narrative has been driven by multi-billion-dollar hyperscaler deals, while FORM's has been powered by record revenue and sharp margin expansion tied to high-bandwidth memory (HBM) demand.
AMD has surged roughly 200% year to date, crossing a $1 trillion market capitalization on AI data-center demand and a "CPU renaissance" narrative. KLAC has gained about 71% year to date, supported by record process-control revenue and rapid growth in advanced packaging for AI chips.
AMD is a large-cap semiconductor designer riding explosive AI compute demand, while ENTG is a mid-cap supplier of materials and purity solutions that feed the same AI-driven chip cycle. AMD recently crossed a $1 trillion market capitalization on surging data center revenue, whereas ENTG operates at a far smaller scale (roughly $23 billion) with steadier, double-digit growth.
VELO closed Tuesday at $9.57, unchanged (+0.00%) from the prior session, with the move occurring during regular market hours. The flat close marked stabilization after Monday's -14.5% plunge, when shares fell to $9.57 from $11.20 following disclosure of CFO James Suva's departure.
The $8 target used here is a technical, publicly discussed recovery objective — not an analyst consensus — because legacy analyst price targets were set before NFE's restructuring and reverse stock split. New Fortress Energy Inc. ( NFE ) trades near $5.51, so reaching $8 implies a roughly 45% advance.
AVBP plunged -46.98% during Tuesday's regular session, closing at $15.09 versus $28.46, marking its worst single-day decline on record. The catalyst was the Phase 3 FURVENT trial of firmonertinib failing its primary endpoint—progression-free survival—in first-line EGFR exon 20 insertion non-small cell lung cancer.
Upcoming catalyst: The company's next earnings release is estimated for November 6, 2026, which should offer fresh detail on its SKY token holdings, staking rewards, and treasury strategy. Strategic positioning: SDEV is an on-chain holding company providing public-market exposure to the Sky protocol ecosystem, with SKY as its core digital asset and a stated focus on the stablecoin economy.
Different roles in the chip ecosystem: AMAT is a materials-engineering and deposition leader, while KLAC dominates process control, inspection, and yield management. Momentum favors AMAT: AMAT shares have more than doubled this year, while KLAC has recently pulled back roughly 9% in a month on margin and execution concerns.